Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Dyne Therapeutics announced participation at the 2026 AMCP Conference with presentations on clinical trial data supporting their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) therapeutics. The company is preparing for potential U.S. launches of DMD treatment next year and DM1 treatment in early 2028, focusing on payer engage…